John Bridgewater - Publications, H-index & Citations

John Bridgewater

University College Hospital

65H指数

452论文数

3.5W被引数

收录论文 144

发表时间

Futibatinib after Non-Covalent FGFR Inhibitors in FGFR2-Rearranged Intrahepatic Cholangiocarcinoma: Clinical Activity and Resistance Patterns 富替比替尼在FGFR2重排型肝内胆管癌中作为非共价FGFR抑制剂后的临床活性及耐药模式

European Journal of Cancer

IF7.1

2026-09-09

PREAI

Simona Casalino; Enza Scarlato; Marina Crespo Cruz; Christoph Gerdes; Anna Sordo; Alberto Quinzii; Camilla Zecchetto; Luisa Messineo; Ester Tasselli; Lucia Mendo; Anna Saborowski; John Bridgewater; Arndt Vogel; Davide Melisi

Advanced Ampullary Cancer: post-hoc analysis of the ABC-01, -02 and -03 clinical trials

The Oncologist

IF0

2025-12-14

OAAI

Angela Lamarca; Paul Ross; Harpreet S Wasan; Richard A Hubner; Mairéad G McNamara; Andre Lopes; Daniel Palmer; Juan W Valle; John Bridgewater

Cholangiocarcinoma 2026: status quo, unmet needs and priorities 胆管癌2026: 现状，未满足的需求和优先事项

Nature Reviews Gastroenterology & Hepatology

IF51

2025-12-10

OAAI

Jesus M. Banales; Pedro M. Rodrigues; Silvia Affò; Jesper B. Andersen; Patricia Aspichueta; Luke Boulter; John Bridgewater; Diego F. Calvisi; Andres Cardenas; Vincenzo Cardinale; Guido Carpino; Cédric Coulouarn; Cristina Dopazo; Julien Edeline; Luca Fabris; Trine Folseraas; Alejandro Forner; Benjamin Goeppert; Mathias Heikenwalder; Timothy J. Kendall; Shahid A. Khan; Heinz-Josef Klümpen; Bas Groot Koerkamp; Angela Lamarca; Stacie Lindsey; Ana Lleo; Tom Luedde; Rocio I. R. Macias; Helen Morement; Jean-Charles Nault; Paula Olaizola; Maria J. Perugorria; Chiara Raggi; Lorenza Rimassa; Anna Saborowski; Juan W. Valle; Mathew Vithayathil; Arndt Vogel; Chiara Braconi

Gain of visceral adipose tissue rather than low skeletal muscle mass is associated with overall survival in patients with colorectal liver metastases; results from the NewEPOC study 内脏脂肪组织增加而非骨骼肌质量降低与结直肠癌肝转移患者的总生存期相关；NewEPOC研究的结果

European Journal of Surgical Oncology

IF2.9

2025-11-19

OAAI

Merel R. Aberle; Marjolein A.P. Ligthart; Malcolm A. West; Sander S. Rensen; Zina Eminton; David P.J. van Dijk; Sian A. Pugh; John A. Bridgewater; John N. Primrose; Steven W.M. Olde Damink

Epigenetically driven and early immune evasion in colorectal cancer evolution 表观遗传驱动的结直肠癌进化中的早期免疫逃逸

Nature Genetics

IF29

2025-11-05

OAAI

Eszter Lakatos; Vinaya Gunasri; Luis Zapata; Jacob Househam; Timon Heide; Nicholas Trahearn; Ottilie Swinyard; Luis Cisneros; Claire Lynn; Maximilian Mossner; Chris Kimberley; Inmaculada Spiteri; George D. Cresswell; Gerard Llibre-Palomar; Miriam Mitchison; Carlo C. Maley; Marnix Jansen; Manuel Rodriguez-Justo; John Bridgewater; Ann-Marie Baker; Andrea Sottoriva; Trevor A. Graham

Opportunities and Approaches to Optimising Advanced Cholangiocarcinoma Outcomes in the Era of Targeted Therapies: A Narrative Review 靶向治疗时代优化晚期胆管癌预后的机遇与方法：一项叙事性综述

Oncology and Therapy

IF3.2

2025-10-08

OAAI

Teresa Macarulla; Cindy Neuzillet; Gerald W. Prager; Lorenza Rimassa; John Bridgewater

The colorectal liver metastasis growth pattern phenotype is not dependent on genotype 结直肠癌肝转移生长模式表型不依赖于基因型

British Journal of Cancer

IF6.8

2025-07-23

OAAI

Diederik J. Höppener; Sanne M. L. Verheul; Pieter M. H. Nierop; Florian E. Buisman; Boris Galjart; Saskia M. Wilting; Siân A. Pugh; Susan D. Richman; Vinod P. Balachandran; William R. Jarnagin; T. Peter Kingham; Peter B. Vermeulen; Jinru Shia; Philip Quirke; John A. Bridgewater; Timothy S. Maughan; Bas Groot Koerkamp; Dirk J. Grünhagen; Cornelis Verhoef; John N. Primrose; Michael I. D’Angelica

Reply to letter comments on: Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine)回复关于以下内容的信件评论：分子靶向维持治疗与标准治疗在晚期胆道癌中的比较：一项国际、随机、对照、开放标签、III期伞式试验（SAFIR-ABC10-精准医学）

ESMO Open

IF8.3

2025-07-18

PREAI

D. Malka; I. Borbath; A. Lopes; T. Vandamme; J. Edeline; J. Bridgewater

Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 候选替代终点与晚期胆道癌总生存率的关系

Journal of Hepatology

IF33

2025-06-03

PREAI

Florian Castet; Carles Fabregat-Franco; John Bridgewater; Jin Won Kim; Margherita Rimini; Adelaida La Casta; Angela Lamarca; Minsu Kang; Francesca Salani; Alfredo Castillo; Andre Lopes; Jaewon Hyung; Lorenza Rimassa; Jorge Adeva; Daniel López-Valbuena; Míriam Basagaña-Farres; Simran Vaja; Ka Man Mak; Tian V. Tian; Andrés Muñoz; Andrea Casadei-Gardini; Changhoon Yoo; Juan W. Valle; Teresa Macarulla

Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10dPrecision Medicine)分子靶向维持治疗与标准治疗在晚期胆道癌中的比较：一项国际、随机、对照、开放标签、III期伞式试验（SAFIR-ABC10dPrecision Medicine）

ESMO OPEN

IF8.3

2025-05-01

PREAI

Malka, D.; Borbath, I.; Lopes, A.; Couch, D.; Jimenez, M.; Vandamme, T.; Valle, J. W.; Wason, J.; Ambrose, E.; Dewever, L.; De Bruyne, I.; Edeline, J.; Bridgewater, J.

Plain language summary: an analysis of the safety of futibatinib treatment in people with different types of cancer 通俗易懂的总结: 不同类型癌症患者使用futibatinib治疗的安全性分析

FUTURE ONCOLOGY

IF2.6

2024-10-28

OAAI

Meric-Bernstam, Funda; Hollebecque, Antoine; Furuse, Junji; Oh, Do-Youn; Bridgewater, John A.; Anderson, Bailey; Hangai, Nanae; Wacheck, Volker; Goyal, Lipika

Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-09-01

PREAI

Mukherjee, Somnath; Qi, Cathy; Shaw, Rachel; Jones, Christopher M.; Bridgewater, John A.; Radhakrishna, Ganesh; Patel, Neel; Holmes, Jane; Virdee, Pradeep S.; Tranter, Bethan; Parsons, Philip; Falk, Stephen; Wasan, Harpreet S.; Ajithkumar, Thankamma, V; Holyoake, Daniel; Roy, Rajarshi; Scott-Brown, Martin; Hurt, Christopher N.; O'Neill, Eric; Sebag-Montefiore, David; Maughan, Tim S.; Hawkins, Maria A.; Corrie, Pippa

A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer

FUTURE ONCOLOGY

IF2.6

2024-08-08

OAAI

Harding, James J.; Fan, Jia; Oh, Do-Youn; Choi, Hye Jin; Kim, Jin Won; Chang, Heung-Moon; Bao, Lequn; Sun, Hui-Chuan; Macarulla, Teresa; Xie, Feng; Metges, Jean-Phillippe; Ying, Jie'er; Bridgewater, John; Lee, Myung-Ah; Tejani, Mohamedtaki A.; Chen, Emerson Y.; Kim, Dong Uk; Wasan, Harpreet; Ducreux, Michel; Bao, Yuanyuan; Lindsey, Stacie; Bachini, Melinda; Morement, Helen; Boyken, Lisa; Ma, Jiafang; Garfin, Phillip; Pant, Shubham

Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy Post Hoc Analysis of the SCOT Randomized Clinical Trial 从结直肠癌手术到辅助化疗的时间SCOT随机临床试验的事后分析

JAMA SURGERY

IF14.9

2024-08-01

PREAI

Gogenur, Mikail; Rosen, Andreas Weinberger; Iveson, Timothy; Kerr, Rachel S.; Saunders, Mark P.; Cassidy, Jim; Tabernero, Josep; Haydon, Andrew; Glimelius, Bengt; Harkin, Andrea; Allan, Karen; Pearson, Sarah; Boyd, Kathleen A.; Briggs, Andrew H.; Waterston, Ashita; Medley, Louise; Ellis, Richard; Dhadda, Amandeep S.; Harrison, Mark; Falk, Stephen; Rees, Charlotte; Olesen, Rene K.; Propper, David; Bridgewater, John; Azzabi, Ashraf; Cunningham, David; Hickish, Tamas; Gollins, Simon; Wasan, Harpreet S.; Kelly, Caroline; Goegenur, Ismail; Hollaender, Niels Henrik

Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer FOENIX-CCA2研究的简明语言摘要: futibatinib用于晚期胆管癌患者

FUTURE ONCOLOGY

IF2.6

2024-06-17

OAAI

Goyal, Lipika; Meric-Bernstam, Funda; Hollebecque, Antoine; Valle, Juan W.; Morizane, Chigusa; Karasic, Thomas B.; Abrams, Thomas A.; Furuse, Junji; Kelley, Robin Katie; Cassier, Philippe A.; Klumpen, Heinz-Josef; Chang, Heung-Moon; Chen, Li-Tzong; Tabernero, Josep; Oh, Do-Youn; Mahipal, Amit; Moehler, Markus; Komatsu, Yoshito; Ahn, Daniel H.; Epstein, Robert S.; Halim, Abdel-Baset; Wacheck, Volker; He, Yaohua; Liu, Mei; Benhadji, Karim A.; Bridgewater, John A.

Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial

HEPATOLOGY

IF15.8

2024-06-14

OAAI

Oh, Do-Youn; Ikeda, Masafumi; Lee, Choong-kun; Rojas, Carlos; Hsu, Chih-Hung; Kim, Jin Won; Shen, Lin; Furuse, Junji; Park, Joon Oh; Borad, Mitesh; de Braud, Filippo; Bridgewater, John; Lee, Sunyoung S.; Moehler, Markus; Audhuy, Francois; Osada, Motonobu; Sato, Masashi; Yoo, Changhoon

A Quality-adjusted Time Without Symptoms and Toxicity (Q-TWiST) analysis comparing nivolumab plus chemotherapy (N plus CT) or nivolumab plus ipilimumab (N plus I) vs CT in patients (pts) with tumor cell PD-L1 ≥ 1% advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648

ANNALS OF ONCOLOGY

IF65.4

2024-06-01

PREAI

Chau, I.; Bridgewater, J. A.; Wyrwicz, L. S.; Greenwood, M.; Blum, S. I.; Moreno-Koehler, A.; Martin, E.; Taylor, F.; Davis, C.; Singh, P.

Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients 不可逆FGFR1-4抑制剂Futibatinib的安全性和不良事件管理: 469例患者的汇总安全性分析

CLINICAL CANCER RESEARCH

IF10.2

2024-02-08

OAAI

Meric-Bernstam, Funda; Hollebecque, Antoine; Furuse, Junji; Oh, Do-Youn; Bridgewater, John A.; Shimura, Masashi; Anderson, Bailey; Hangai, Nanae; Wacheck, Volker; Goyal, Lipika

Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study

MOLECULAR CANCER THERAPEUTICS

IF5.5

2023-12-01

PREAI

Schram, Alison M.; Subbiah, Vivek; Liao, Chih-Yi (Andy); Moreno, Victor; Desamparados, Roda; Ponz-Sarvise, Mariano; Dotan, Efrat; Cassier, Philippe Alexandre; Moreno, Irene; Varkaris, Andreas; Kim, Richard D.; Garralda, Elena; Opdam, Frans; Tai, David; Italiano, Antoine; Oh, Do-Youn; Goyal, Lipika; Fontana, Elise; Liu, Jia; Boukovala, Myrto; Ghiringelli, Francois; Borad, Mitesh J.; Babiker, Hani; Jin, Zhaohui; Millward, Michael; Yachnin, Jeffrey; Kamath, Suneel Deepak; Coward, Jermaine M.; Yoo, Changhoon; Kelley, Robin Kate; Sahai, Vaibhav; Bridgewater, John; Springfield, Christoph; Florou, Vaia; El-Khoueiry, Anthony; Eskens, Ferry; Lin, Bruce; Paulson, Scott; Curigliano, Giuseppe; Murphy, Meredith; Deary, Alicia; Ricard, Fabien; Jen, Kai Yu; Ramirez, Florence (Tianhui); Blakesley, Rick E.; Schmidt-Kittler, Oleg; Mar, Brenton G.; Park, Joon Oh; Hollebecque, Antoine

Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Wasan, H. S.; Harding, J. J.; Fan, J.; Oh, D-Y.; Choi, H. J.; Kim, J. W.; Chang, H-M.; Bao, L.; Sun, H.; Macarulla, T.; Xie, F.; Metges, J-P.; Ying, J.; Bridgewater, J. A.; Tejani, M.; Chen, E. Y.; Ducreux, M. P.; Ma, J.; Garfin, P.; Pant, S.

研究方向